<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="GastroenterologyGreece pmcid: 7049240AnnGastroenterol-33-195 doi: 10.20524/aog.2020.0449 : Original Article Direct-acting antiviral" exact="treatment" post="for chronic hepatitis C in people who use drugs"/>
 <result pre="factors associated with a sustained virological response 12 weeks after" exact="treatment" post="completion (SVR12) and LTFU. Results Patients’ mean age was"/>
 <result pre="was 48±9.2 years and 91/174 (52.3%) were attending opioid substitution" exact="treatment" post="programs. Overall, 144/174 (82.8%) patients completed therapy and presented"/>
 <result pre="and presented for SVR12 testing, 8/174 (4.6%) did not complete" exact="treatment" post="and 22/174 (12.6%) were LTFU. Overall SVR12 was 79.9%"/>
 <result pre="was found to have a trend towards LTFU. Conclusions HCV" exact="treatment" post="by hepatologists and addiction specialists is feasible, effective and"/>
 <result pre="should be placed on interventions guaranteeing follow up for SVR" exact="testing" post="and general care. Direct-acting antivirals hepatitis C virus infection"/>
 <result pre="SVR testing and general care. Direct-acting antivirals hepatitis C virus" exact="infection" post="people who inject drugs sustained virological response lost to"/>
 <result pre="Approximately 10% of people with chronic hepatitis C virus (HCV)" exact="infection" post="globally are past or current illicit drug users [1]."/>
 <result pre="the main route of HCV transmission in developed countries. HCV" exact="infection" post="poses an important health issue among PWID, while in"/>
 <result pre="is a need to prioritize PWID for scaling up HCV" exact="testing" post="and treatment. The clear benefit of antiviral therapy after"/>
 <result pre="the concerns regarding adherence, reinfection and overall outcome of anti-HCV" exact="treatment" post="in PWID. Several reports from different countries have shown"/>
 <result pre="in PWID. Several reports from different countries have shown that" exact="treatment" post="uptake still remains low [8] and many clinicians are"/>
 <result pre="of America active substance use remains an important barrier to" exact="treatment" post="uptake [10]. On the other hand, PWID are facing"/>
 <result pre="in PWID offers sustained virological response rates 12 weeks after" exact="treatment" post="completion (SVR12) similar to those in non-PWID populations [11-16]."/>
 <result pre="of LTFU and the factors that may affect engagement with" exact="treatment" post="and follow up will add crucial information to improve"/>
 <result pre="contribute to the WHO strategy for HCV elimination, by scaling-up" exact="treatment" post="for HCV infection in both the general population and"/>
 <result pre="WHO strategy for HCV elimination, by scaling-up treatment for HCV" exact="infection" post="in both the general population and the vulnerable population"/>
 <result pre="the general population and the vulnerable population of PWID. The" exact="prevalence" post="of HCV infection in Greece is estimated to be"/>
 <result pre="and the vulnerable population of PWID. The prevalence of HCV" exact="infection" post="in Greece is estimated to be between 0.83% and"/>
 <result pre="primary objective was to evaluate the clinical outcome of HCV" exact="treatment" post="with DAAs in a Greek cohort of PWID, as"/>
 <result pre="analysis of a cohort that included PWID with chronic HCV" exact="infection" post="who had been treated with DAAs in our tertiary"/>
 <result pre="RNA for at least 6 months and had started antiviral" exact="treatment" post="with DAAs between 1 September 2014 and 1 June"/>
 <result pre="were not considered exclusion criteria in our analysis. Opioid substitution" exact="treatment" post="(OST) programs included substitution therapies with buprenorphine or methadone"/>
 <result pre="the practitioners at the addiction programs. The decision for antiviral" exact="treatment" post="initiation was made by an expert physician, and in"/>
 <result pre="and liver disease stages were also taken into consideration for" exact="treatment" post="initiation. In Greece, reimbursement for DAAs was based on"/>
 <result pre="(Metavir score F3), and cirrhosis (Metavir Score F4), respectively. The" exact="diagnosis" post="of cirrhosis was based on the transient elastography score"/>
 <result pre="were determined using standard commercial assays. We also recorded all" exact="treatment" post="medications, HCV treatment plans, all visits to our center,"/>
 <result pre="standard commercial assays. We also recorded all treatment medications, HCV" exact="treatment" post="plans, all visits to our center, treatment completion data"/>
 <result pre="treatment medications, HCV treatment plans, all visits to our center," exact="treatment" post="completion data and SVR12 testing results. The specific DAA"/>
 <result pre="all visits to our center, treatment completion data and SVR12" exact="testing" post="results. The specific DAA treatment was determined according to"/>
 <result pre="treatment completion data and SVR12 testing results. The specific DAA" exact="treatment" post="was determined according to the physician’s judgment, taking into"/>
 <result pre="genotype, and the presence of cirrhosis and comorbidities. During the" exact="treatment" post="period, all patients were assessed monthly in our department"/>
 <result pre="period, all patients were assessed monthly in our department for" exact="treatment" post="compliance, or earlier if possible adverse effects of therapy"/>
 <result pre="chain reaction test with undetectable HCV RNA, 12 weeks after" exact="treatment" post="completion. Individuals who did not complete the SVR12 testing"/>
 <result pre="after treatment completion. Individuals who did not complete the SVR12" exact="testing" post="within 24 weeks after treatment completion were considered as"/>
 <result pre="did not complete the SVR12 testing within 24 weeks after" exact="treatment" post="completion were considered as LTFU. Failure to respond to"/>
 <result pre="therapy was defined as detectable HCV RNA any time after" exact="treatment" post="completion. The study was approved by the Ethics committee"/>
 <result pre="the univariate analysis were included in the multivariate model. Statistical" exact="tests" post="were performed using SPSS (version 25). A P-value &amp;lt;0.05"/>
 <result pre="2014 and 1 June 2018 and were due for SVR12" exact="testing" post="by 31st December 2018. The baseline characteristics of our"/>
 <result pre="PWID, 91 (52.3%) were attending OST programs during the DAA" exact="treatment" post="period and 68 (39.1%) revealed parallel active drug use."/>
 <result pre="HIV/HCV coinfection were under highly active antiretroviral therapy. Previous HCV" exact="treatment" post="experience was reported by 44 of the 174 (25.3%)"/>
 <result pre="Table 2. Table 1 Baseline characteristics of PWID who initiated" exact="treatment" post="with DAAs Table 2 Antiviral treatment options for the"/>
 <result pre="of PWID who initiated treatment with DAAs Table 2 Antiviral" exact="treatment" post="options for the 174 PWID who initiated DAAs, n"/>
 <result pre="for early cessation (4/8 patients); one patient died early after" exact="treatment" post="initiation; one patient discontinued treatment because of pregnancy; and"/>
 <result pre="one patient died early after treatment initiation; one patient discontinued" exact="treatment" post="because of pregnancy; and 2 patients were diagnosed with"/>
 <result pre="with malignancies (acute leukemia and rectal cancer) and discontinued DAA" exact="treatment" post="on their own decision. Two of them, who had"/>
 <result pre="on their own decision. Two of them, who had HCV" exact="testing" post="approximately 1 year after treatment discontinuation, showed a sustained"/>
 <result pre="of them, who had HCV testing approximately 1 year after" exact="treatment" post="discontinuation, showed a sustained virological response. Between treatment initiation"/>
 <result pre="year after treatment discontinuation, showed a sustained virological response. Between" exact="treatment" post="initiation and the end of treatment (EoT), 4 (2.3%)"/>
 <result pre="sustained virological response. Between treatment initiation and the end of" exact="treatment" post="(EoT), 4 (2.3%) of the 174 patients were LTFU,"/>
 <result pre="patients were LTFU, while 18 (10.3%) patients were LTFU after" exact="treatment" post="completion; therefore, overall 22/174 (12.6%) patients were LTFU with"/>
 <result pre="were LTFU with no SVR12 test available. Serum HCV RNA" exact="testing" post="12 weeks after the EoT was performed in 144/174"/>
 <result pre="end of treatment; SVR12, sustained virological response 12 weeks after" exact="treatment" post="completion Univariate and multivariate analyses were performed to identify"/>
 <result pre="and tolerability No serious adverse event was reported during the" exact="treatment" post="period and no patient stopped therapy because of adverse"/>
 <result pre="half years from a cohort of PWID with chronic HCV" exact="infection" post="treated with DAAs. Our results clearly showed that DAAs"/>
 <result pre="goal. The efficacy of DAA therapy in PWID with HCV" exact="infection" post="has been examined in 2 large prospective studies, in"/>
 <result pre="patients who had an HCV RNA test 12 weeks post" exact="treatment" post="is comparable with the results of these prospective studies,"/>
 <result pre="our population achieved SVR12, with the absence of HCV RNA" exact="testing" post="after treatment completion being the main reason for the"/>
 <result pre="achieved SVR12, with the absence of HCV RNA testing after" exact="treatment" post="completion being the main reason for the lower SVR12."/>
 <result pre="between 80-87% [19,20,27]. Furthermore, the percentage of 10.3% LTFU after" exact="treatment" post="completion was similar to that in several real-world studies"/>
 <result pre="across the studies might be related to the context of" exact="treatment" post="delivery and follow up (i.e., frequency of study visits,"/>
 <result pre="our cohort we observed that 55 patients underwent SVR12 lab" exact="testing" post="after the 12th post-therapy week, while the mean time"/>
 <result pre="while the mean time to SVR12 was 19 weeks after" exact="treatment" post="completion; therefore, an extended follow up in the PWID"/>
 <result pre="be a reasonable option for SVR12 assessment. Serum HCV RNA" exact="testing" post="12 weeks after treatment completion and long-term follow up"/>
 <result pre="for SVR12 assessment. Serum HCV RNA testing 12 weeks after" exact="treatment" post="completion and long-term follow up is of major clinical"/>
 <result pre="argued, however, that in the era of HCV elimination, post-therapy" exact="testing" post="and care may not be the priority; however, a"/>
 <result pre="reinfection rate assessment after therapy and surveillance for the early" exact="diagnosis" post="of hepatocellular carcinoma are important clinical issues from an"/>
 <result pre="view [30]. Identifying factors that can predict lower adherence during" exact="treatment" post="or loss during the follow-up period might be helpful"/>
 <result pre="lifestyle and a higher probability of failure to comply with" exact="treatment" post="and follow-up schedules [32]. Interestingly, in the multivariate regression"/>
 <result pre="The results are in accordance with our previous analysis regarding" exact="treatment" post="uptake: a proportion of PWID with HCV infection did"/>
 <result pre="analysis regarding treatment uptake: a proportion of PWID with HCV" exact="infection" post="did not start treatment, despite the availability DAA, and"/>
 <result pre="start treatment, despite the availability DAA, and the probability of" exact="treatment" post="initiation was negatively associated with ongoing benzodiazepine use [33]."/>
 <result pre="Treatment adherence-enhancing strategies, including special nurses engaged in hepatitis C" exact="treatment" post="in the hospital settings, could be a promising approach"/>
 <result pre="Overall, DAA therapy was well-tolerated and safe; 3 patients discontinued" exact="treatment" post="for non-liver-related reasons and 1 with decompensated disease at"/>
 <result pre="patients receiving ribavirin. Neither of these patients needed to discontinue" exact="treatment" post="and their anemia improved with ribavirin dose reduction. In"/>
 <result pre="addition, none of the treated PWID developed hepatocellular carcinoma between" exact="treatment" post="initiation and SVR12 testing. Our study had several limitations,"/>
 <result pre="infection; therefore, PWID should no longer face barriers to HCV" exact="treatment" post="access. However, in a real-world setting 1 of 10"/>
 <result pre="order to develop strategies to reduce LTFU, improve care and" exact="testing" post="and get closer to HCV elimination. Summary Box What"/>
 <result pre="already known: Direct acting-antivirals (DAAs) are highly effective for the" exact="treatment" post="of hepatitis C virus (HCV) infection Compared to the"/>
 <result pre="highly effective for the treatment of hepatitis C virus (HCV)" exact="infection" post="Compared to the general population, DAAs have shown similar"/>
 <result pre="trials in people who inject drugs (PWID) and have HCV" exact="infection" post="There has been evidence for lower response rates for"/>
 <result pre="to DAA therapy and loss to follow up (LTFU) during" exact="treatment" post="are major concerns regarding antiviral treatment in the PWID"/>
 <result pre="follow up (LTFU) during treatment are major concerns regarding antiviral" exact="treatment" post="in the PWID population What the new findings are:"/>
 <result pre="Approximately 1 of 10 PWID was LTFU during or after" exact="treatment" post="completion, with no SVR test available LTFU seems to"/>
 <result pre="2MyersRPKrajdenMBilodeauMet al.Burden of disease and cost of chronic hepatitis C" exact="infection" post="in CanadaCan J Gastroenterol Hepatol20142824325024839620 3MartinNKVickermanPGrebelyJet al.Hepatitis C virus"/>
 <result pre="infection in CanadaCan J Gastroenterol Hepatol20142824325024839620 3MartinNKVickermanPGrebelyJet al.Hepatitis C virus" exact="treatment" post="for prevention among people who inject drugs:Modeling treatment scale-up"/>
 <result pre="C virus treatment for prevention among people who inject drugs:Modeling" exact="treatment" post="scale-up in the age of direct-acting antiviralsHepatology2013581598160923553643 4van der"/>
 <result pre="disorders in the direct-acting-antiviral period?Hepatology201969516330019478 9AsherAKPortilloCJCooperBADawson-RoseCVlahovDPageKAClinicians'views of hepatitis C virus" exact="treatment" post="candidacy with direct-acting antiviral regimens for people who inject"/>
 <result pre="Use Misuse2016511218122327219274 10BaruaSGreenwaldRGrebelyJDoreGJSwanTTaylorLERestrictions for Medicaid reimbursement of sofosbuvir for the" exact="treatment" post="of hepatitis C virus infection in the United StatesAnn"/>
 <result pre="reimbursement of sofosbuvir for the treatment of hepatitis C virus" exact="infection" post="in the United StatesAnn Intern Med201516321522326120969 11AlimohammadiAHoleksaJThiamATruongDConwayBReal-world efficacy of"/>
 <result pre="Intern Med201516321522326120969 11AlimohammadiAHoleksaJThiamATruongDConwayBReal-world efficacy of direct-acting antiviral therapy for HCV" exact="infection" post="affecting people who inject drugs delivered in a multidisciplinary"/>
 <result pre="in a multidisciplinary settingOpen Forum Infect Dis20185ofy12029992173 12ChristensenSBuggischPMaussSet al.Direct-acting antiviral" exact="treatment" post="of chronic HCV-infected patients on opioid substitution therapy:still a"/>
 <result pre="al.collab: C-EDGE CO-STAR Study GroupElbasvir-grazoprevir to treat hepatitis C virus" exact="infection" post="in persons receiving opioid agonist therapy:a randomized trialAnn Intern"/>
 <result pre="and without ribavirin in patients with chronic HCV genotype 1" exact="infection" post="receiving opioid substitution therapy:analysis of Phase 3 ION trialsClin"/>
 <result pre="safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus" exact="infection" post="receiving opioid substitution therapy:analysis of Phase 3 ASTRAL trialsClin"/>
 <result pre="al.collab: SIMPLIFY Study GroupSofosbuvir and velpatasvir for hepatitis C virus" exact="infection" post="in people with recent injection drug use (SIMPLIFY):an open-label,"/>
 <result pre="NicolòAet al.Treatment with direct-acting antiviral agents of hepatitis C virus" exact="infection" post="in injecting drug users:A prospective studyJ Viral Hepat20172485085728345206 19ButnerJLGuptaNFabianCHenrySShiJMTetraultJMOnsite"/>
 <result pre="infection in injecting drug users:A prospective studyJ Viral Hepat20172485085728345206 19ButnerJLGuptaNFabianCHenrySShiJMTetraultJMOnsite" exact="treatment" post="of HCV infection with direct acting antivirals within an"/>
 <result pre="drug users:A prospective studyJ Viral Hepat20172485085728345206 19ButnerJLGuptaNFabianCHenrySShiJMTetraultJMOnsite treatment of HCV" exact="infection" post="with direct acting antivirals within an opioid treatment programJ"/>
 <result pre="of HCV infection with direct acting antivirals within an opioid" exact="treatment" post="programJ Subst Abuse Treat201775495328237054 20MasonKDoddZGuytonMet al.Understanding real-world adherence in"/>
 <result pre="an urban primary care clinicInt J Drug Policy20174719620128811158 22PapatheodoridisGSypsaVKantzanouMNikolakopoulosIHatzakisAEstimating the" exact="treatment" post="cascade of chronic hepatitis B and C in Greece"/>
 <result pre="25TriantosCKonstantakisCTselekouniPKalafateliMAggeletopoulouIManolakopoulosSEpidemiology of hepatitis C in GreeceWorld J Gastroenterol2016228094810227688651 26ManolakopoulosSDeutschMJAnagnostouOet al.Substitution" exact="treatment" post="or active intravenous drug use should not be contraindications"/>
 <result pre="active intravenous drug use should not be contraindications for antiviral" exact="treatment" post="in drug users with chronic hepatitis CLiver Int2010301454146020846344 27MorrisLSmirnovAKvassayAet"/>
 <result pre="CLiver Int2010301454146020846344 27MorrisLSmirnovAKvassayAet al.Initial outcomes of integrated community-based hepatitis C" exact="treatment" post="for people who inject drugs:Findings from the Queensland Injectors'Health"/>
 <result pre="the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the" exact="treatment" post="of chronic hepatitis C virus infection in the German"/>
 <result pre="and dasabuvir for the treatment of chronic hepatitis C virus" exact="infection" post="in the German Hepatitis C RegistryJ Viral Hepat20172484084928342229 30KoustenisK-RKoutliEKranidiotiHet"/>
 <result pre="follow-up of people who inject drugs (PWID) after the successful" exact="treatment" post="of chronic hepatitis C with direct-acting antivirals (DAA)Gastroenterology2019156S-1346 31HajarizadehBCunninghamEBReidHLawMDoreGJGrebelyJDirect-acting"/>
 <result pre="of chronic hepatitis C with direct-acting antivirals (DAA)Gastroenterology2019156S-1346 31HajarizadehBCunninghamEBReidHLawMDoreGJGrebelyJDirect-acting antiviral" exact="treatment" post="for hepatitis C among people who use or inject"/>
 <result pre="al.The impact of injecting networks on hepatitis C transmission and" exact="treatment" post="in people who inject drugsHepatology2014601861187025163856 33AnagnostouOKranidiotiCMichaKet al.Is the availability"/>
</results>
